Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Goodwill & Intangibles: 2010-2025

Historic Goodwill & Intangibles for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $6.9 million.

  • Arrowhead Pharmaceuticals' Goodwill & Intangibles fell 19.87% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 19.87%. This contributed to the annual value of $6.9 million for FY2025, which is 19.87% down from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Goodwill & Intangibles stood at $6.9 million, which was down 5.83% from $7.3 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Goodwill & Intangibles' 5-year high stood at $14.5 million during Q1 2021, with a 5-year trough of $6.9 million in Q3 2025.
  • For the 3-year period, Arrowhead Pharmaceuticals' Goodwill & Intangibles averaged around $9.0 million, with its median value being $9.0 million (2024).
  • Data for Arrowhead Pharmaceuticals' Goodwill & Intangibles shows a maximum YoY dropped of 19.87% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Goodwill & Intangibles stood at $13.2 million in 2021, then dropped by 12.85% to $11.5 million in 2022, then fell by 14.74% to $9.8 million in 2023, then fell by 17.28% to $8.1 million in 2024, then decreased by 19.87% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, $7.3 million for Q2 2025, and $7.7 million during Q1 2025.